Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Harry Hendrikse

Showing results (1-10 of 74) with videos related to

Pageof 8
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 6, 2007
In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinicallyKiichi Ishiwata, Kazunori Kawamura, Kazuhiko Yanai, et al.
Nuclear Medicine Communications|May 18, 2022
Anatomical breast imaging-derived parameters do not provide incremental information in prediction of nonvisualization of sentinel lymph nodes on lymphoscintigraphyYoussef Chahid, Hein J Verberne, Edwin Poel, et al.
Current Opinion in Drug Discovery & Development|August 30, 2008
Positron emission tomography for modeling pathophysiological processes in vivoN Harry Hendrikse, Gert Luurtsema, Astrid A M van der Veldt, et al.
Current Pharmaceutical Design|May 12, 2004
PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNSPhilip H Elsinga, N Harry Hendrikse, Joost Bart, et al.
Molecular Imaging and Biology|May 25, 2005
Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brainPhilip H Elsinga, N Harry Hendrikse, Joost Bart, et al.
Current Pharmaceutical Design|November 11, 2008
Individualized treatment planning in oncology: role of PET and radiolabelled anticancer drugs in predicting tumour resistanceAstrid A M van der Veldt, Gert Luurtsema, Mark Lubberink, et al.
Bone|August 7, 2016
Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastasesRogier Lange, Rob Ter Heine, Russ Ff Knapp, et al.
Journal of Labelled Compounds & Radiopharmaceuticals|February 19, 2015
Synthesis of [3-N-(11) C-methyl]temozolomide via in situ activation of 3-N-hydroxymethyl temozolomide and alkylation with [(11) C]methyl iodideJonas Eriksson, Rolph Van Kooij, Robert C Schuit, et al.
Cancers|March 10, 2022
Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate CancerWietske I Luining, Matthijs C F Cysouw, Dennie Meijer, et al.
Nuclear Medicine Communications|February 4, 2015
Untangling the web of European regulations for the preparation of unlicensed radiopharmaceuticals: a concise overview and practical guidance for a risk-based approachRogier Lange, Rob ter Heine, Clemens Decristoforo, et al.
Pageof 8

Showing results (1-10 of 74) with videos related to

Sort By:
Pageof 8
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 6, 2007
In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinicallyKiichi Ishiwata, Kazunori Kawamura, Kazuhiko Yanai, et al.
Nuclear Medicine Communications|May 18, 2022
Anatomical breast imaging-derived parameters do not provide incremental information in prediction of nonvisualization of sentinel lymph nodes on lymphoscintigraphyYoussef Chahid, Hein J Verberne, Edwin Poel, et al.
Current Opinion in Drug Discovery & Development|August 30, 2008
Positron emission tomography for modeling pathophysiological processes in vivoN Harry Hendrikse, Gert Luurtsema, Astrid A M van der Veldt, et al.
Current Pharmaceutical Design|May 12, 2004
PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNSPhilip H Elsinga, N Harry Hendrikse, Joost Bart, et al.
Molecular Imaging and Biology|May 25, 2005
Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brainPhilip H Elsinga, N Harry Hendrikse, Joost Bart, et al.
Current Pharmaceutical Design|November 11, 2008
Individualized treatment planning in oncology: role of PET and radiolabelled anticancer drugs in predicting tumour resistanceAstrid A M van der Veldt, Gert Luurtsema, Mark Lubberink, et al.
Bone|August 7, 2016
Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastasesRogier Lange, Rob Ter Heine, Russ Ff Knapp, et al.
Journal of Labelled Compounds & Radiopharmaceuticals|February 19, 2015
Synthesis of [3-N-(11) C-methyl]temozolomide via in situ activation of 3-N-hydroxymethyl temozolomide and alkylation with [(11) C]methyl iodideJonas Eriksson, Rolph Van Kooij, Robert C Schuit, et al.
Cancers|March 10, 2022
Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate CancerWietske I Luining, Matthijs C F Cysouw, Dennie Meijer, et al.
Nuclear Medicine Communications|February 4, 2015
Untangling the web of European regulations for the preparation of unlicensed radiopharmaceuticals: a concise overview and practical guidance for a risk-based approachRogier Lange, Rob ter Heine, Clemens Decristoforo, et al.
Pageof 8